Skip to main content
spacbrain

ZyVersa Therapeutics

Closed (deSPAC)

Health Care · clinical stage specialty biopharmaceuticals

What it is
Therapeutics, Inc
What it’s doing now
Merging with Larkspur Health Acquisition Corp. (LSPR) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Therapeutics, Inc. ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address high unmet medical needs in the areas of renal and inflammatory diseases. ZyVersa’s development pipeline includes phase 2a ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has potential to treat other glomerular diseases, including Alport syndrome and diabetic kidney disease. ZyVersa’s development pipeline also includes IC 100, a novel inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases. For more information, please visit www.zyversa.com . Cautionary Statement Regarding

Source: S-4/A, accession 0001213900-22-069082

What the company says about itself

Web research — not audited

ZyVersa Therapeutics is committed to improving health outcomes and quality of life for patients with inflammatory and renal diseases. The company is developing IC 100, a novel monoclonal antibody that inhibits the adaptor ASC component of inflammasomes to block inflammatory cascades, and VAR 200, a cholesterol efflux mediator designed to remove excess cholesterol from the kidney's filtration system in chronic kidney diseases.

Markets:
inflammatory diseases | renal diseases | chronic kidney diseases
Products:
IC 100 | VAR 200
What our web check found

[WEB-INTEL 2026-08-26] 8 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Raised $4.1 Million in 2025" [https://investors.zyversa.com/news-releases/news-release-details/zyversa-therapeutics-reports-full-year-2025-financial-results] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Raised $1 Million in Q1-2026" [https://www.globenewswire.com/news-release/2026/05/13/3294491/0/en/zyversa-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "ZyVersa expects its cash of $0.3 million as of March 31, 2026" [https://www.globenewswire.com/news-release/2026/05/13/3294491/0/en/zyversa-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Issued $1M convertible notes on Feb 27, 2026" [https://www.marketscreener.com/news/zyversa-therapeutics-inc-announced-that-it-has-received-1-million-in-funding-ce7e5fdbd08bf223] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Cash on hand was $0.5 million as of September 30, 2025" [https://investors.zyversa.com/node/9296/pdf] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Raised approximately $2.05 million in Q3-2025" [https://investors.zyversa.com/node/9296/pdf] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Raised approximately $2.05 million since the end of Q2-2025" [https://investors.zyversa.com/node/9216/pdf] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Year-end cash fell to $0.1M" [https://www.stocktitan.net/news/ZVSA/zy-versa-therapeutics-reports-full-year-2025-financial-results-and-8slgv5qfl2tw.html]

Source: https://www.zyversa.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

ZyVersa Therapeutics is merging with Larkspur Health Acquisition Corp. (LSPR) currently marked Closed (deSPAC).

Headline equity value—

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is ZyVersa Therapeutics going public?

ZyVersa Therapeutics has an approved merger with the SPAC Larkspur Health Acquisition Corp. (LSPR). Deal status: Closed (deSPAC).

Does ZyVersa Therapeutics have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals